HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 6 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $12,547,134 | -19.6% | 328,459 | -24.1% | 1.70% | -11.0% |
Q2 2023 | $15,614,018 | -4.6% | 432,881 | +1.0% | 1.91% | -8.8% |
Q1 2023 | $16,367,088 | -34.9% | 428,570 | -3.0% | 2.09% | -37.9% |
Q4 2022 | $25,138,932 | +42.5% | 441,809 | -1.0% | 3.37% | +42.0% |
Q3 2022 | $17,637,000 | -26.8% | 446,049 | -18.5% | 2.37% | -11.4% |
Q2 2022 | $24,085,000 | +65.6% | 547,381 | +50.1% | 2.68% | +94.3% |
Q1 2022 | $14,545,000 | -1.4% | 364,718 | -0.6% | 1.38% | +18.3% |
Q4 2021 | $14,753,000 | -41.5% | 366,897 | -40.8% | 1.16% | -44.7% |
Q3 2021 | $25,212,000 | +3.1% | 619,766 | +15.1% | 2.11% | +6.8% |
Q2 2021 | $24,460,000 | +8.1% | 538,656 | -0.8% | 1.97% | -0.8% |
Q1 2021 | $22,628,000 | -16.1% | 542,764 | -14.1% | 1.99% | -13.5% |
Q4 2020 | $26,984,000 | +71.9% | 631,807 | +5.7% | 2.30% | +73.4% |
Q3 2020 | $15,702,000 | +31.3% | 597,477 | +33.9% | 1.32% | +25.3% |
Q2 2020 | $11,959,000 | – | 446,070 | – | 1.06% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SNYDER CAPITAL MANAGEMENT L P | 4,324,232 | $165,185,662 | 3.73% |
Steamboat Capital Partners, LLC | 196,898 | $7,521,504 | 2.79% |
2Xideas AG | 600,799 | $22,950,522 | 2.54% |
BERNZOTT CAPITAL ADVISORS | 171,808 | $6,563,066 | 2.26% |
Redwood Investments, LLC | 328,459 | $12,547,134 | 1.70% |
Mesirow Institutional Investment Management, Inc. | 380,415 | $14,531,853 | 1.47% |
Granite Investment Partners, LLC | 856,253 | $32,708,865 | 1.37% |
Penn Capital Management Company, LLC | 324,707 | $12,453,211 | 1.28% |
EFG Asset Management (North America) Corp. | 137,739 | $5,262,319 | 1.25% |
First Light Asset Management, LLC | 313,536 | $11,977,075 | 1.14% |